Bag, humor me just for a minute and pull into a rest area on that "high road" you like to think you travel when considering all things DNAP.......Help an average sharholder make some sense of recent DNAP goings on based on what little information we have access to.
Richard Gabriel's history prior to DNAP was not terribly impressive, his background reads fairly run of the mill (for a senior level executive). But DNAP being in the state it was at the time, could not hope to attract top tier, proven talent so Richard talks his way in because Dr T is desperate to get back to work on scientific endeavors. Soon after he drags Monica in on the financial side.(After an exhaustive nationwide search, no doubt)
The one thing he might have had was some connections. One of these connections was Biofrontera. What that company is doing seems quite positive and all the reaction to the deal between DNAP and Biofrontera was upbeat. Now we know that deal is no longer possible. Richard still doesn't think he needs to bother with any kind of shareholder communication, although he was full of singing its praises when the deal was announced.
My point is, Richard (and Monica) have come on board at no small expense to us investors. Since they have arrived the only tangible thing that has happened is that the share price has tanked.
Ovanome, Statinome and Forensics all were underway before they arrived. It would seem logical that these projects would be at the same stage(s) in their individual development with or without Gabriel.
The company seemed to genuinely make a effort to communicate with shareholders before these two arrived.
Under Richards' stewardship we have a sub-penny share price, a seemingly positive deal go bust and other than SEC mandated reporting, no communication what so ever from the company as to what is going on and when.
Why would the view from the high road you ride on of Gabriel's performance be any different from the view I see from way down here?
News 
Market Data 
Discover 
AI
